Advances in chemical pharmacotherapy for the treatment of pediatric immune thrombocytopenia

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children. Report from an international working group. Blood. 2009;113(11):2386–2393.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186.
   PubMed Web of Science ®Google Scholar
• Kapur R, Semple JW. Platelets as immune-sensing cells. Blood Adv. 2016;1(1):10–14.
   PubMed Web of Science ®Google Scholar
• Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264–274.
   PubMed Web of Science ®Google Scholar
• Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Microbiol. 2014;12(6):426.
   PubMed Web of Science ®Google Scholar
• Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med. 2008;359(12):1261–1270.
   PubMed Web of Science ®Google Scholar
• Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112(10):4003–4008.
   PubMed Web of Science ®Google Scholar
• Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr. 1966;68(6):971–979.
   PubMed Web of Science ®Google Scholar
• Sartorius JA. Steroid treatment of idiopathic thrombocytopenic purpura in children. Am J Pediatr Hematol Oncol. 1984;6(2):165–169.
   PubMedGoogle Scholar
• Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Ped Hematol Oncol. 1984;6(4):355–361.
   PubMedGoogle Scholar
• Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123(6):989–995.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PHB, Dickerhoff R, Vora AJ. The nontreatment of childhood ITP (or “The art of medicine consists of amusing the patient until nature cures the disease”). Semin Thromb Haemost. 2001;27(3):269–275.
   PubMed Web of Science ®Google Scholar
• Kühne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122–2125.
   PubMed Web of Science ®Google Scholar
• Treutiger I, Rajantie J, Zeller B, et al. Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity? Arch Dis Child. 2007;92(8):704–707.
   PubMed Web of Science ®Google Scholar
• Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. Arch Dis Child. 1992;67(8):1056–1058.
   PubMed Web of Science ®Google Scholar
• Witmer CM, Lambert MP, O’Brien SH, et al. Multicenter cohort study comparing U.S. Management of inpatient pediatric immune thrombocytopenia to current treatment guidelines. Pediatr Blood Cancer. 2016;63(7):1227–1231.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Nordon C, Leblanc T, et al. Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer. 2017;64:e26389 [EPub].
   Web of Science ®Google Scholar
• Schoettler ML, Graham D, Tao W, et al. Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management assessment and management plan (SCAMP®). Pediatr Blood Cancer. 2017;64(5):e26303 [EPub].
   Web of Science ®Google Scholar
• Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141(5):683–688.
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, d’Appuzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1317(8232):1228–1231.
   Google Scholar
• Mayer B, Depré F, Ringel F, et al. New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia. Vox Sang. 2017;112(1):64–69.
   PubMed Web of Science ®Google Scholar
• Tamminga R, Berchtold W, Bruin M, et al. Possible lower rate of chronic ITP after IVIG for acute childhood ITP. An analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol. 2009;146(2):180–184.
   PubMed Web of Science ®Google Scholar
• Heitink-Pollé KMJ, Nijsten J, Boonacker CWB, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295–3307.
   PubMed Web of Science ®Google Scholar
• Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344(8924):703–707.
   PubMed Web of Science ®Google Scholar
• Lazarus A. Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity. J Clin Immunol. 2010;30(Suppl S1):S20–S23.
   PubMedGoogle Scholar
• Washburna N, Schwabb I, Ortiza D, et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A. 2015;112(11):E1297–306.
   PubMed Web of Science ®Google Scholar
• Zhou H, Olsen H, So E, et al. A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b. Blood Adv. 2017;1(8):504–515.
   PubMed Web of Science ®Google Scholar
• Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106(5):1532–1537.
   PubMed Web of Science ®Google Scholar
• Meyer O, Kiesewetter H, Hermsen M, et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer. 2006;47(5 Suppl):721–722.
   PubMed Web of Science ®Google Scholar
• Trebo MM, Frey E, Gadner H, et al. Subcutaneous anti-D globulin application is a safe treatment option of immune thrombocytopenia in children. Ann Hematol. 2010;89(4):415–418.
   PubMed Web of Science ®Google Scholar
• Andersen J. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994;330(22):1560–1564.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264–1271.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401–1407.
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123(25):3906–3908.
   PubMed Web of Science ®Google Scholar
• Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302.
   PubMed Web of Science ®Google Scholar
• Chapin J, Lee CS, Zhang H, et al. Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016;91(9):907–911.
   PubMed Web of Science ®Google Scholar
• Kühne T, Freedman J, Semple JW, et al. Platelet and immune responses to oral cyclic dexamethasone in childhood chronic immune thrombocytopenic purpura. J Pediatr. 1997;130(1):17–24.
   PubMed Web of Science ®Google Scholar
• Guidry JA, George JN, Vesely SK, et al. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83:175–182.
   PubMed Web of Science ®Google Scholar
• Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–82.
   PubMed Web of Science ®Google Scholar
• Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371–377.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–3236.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653–1661.
   PubMed Web of Science ®Google Scholar
• Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–1547.
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Takahashi Y, Hayakawa A, et al. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol. 2014;99(4):429–436.
   PubMed Web of Science ®Google Scholar
• Oved JH, Lee CSY, Bussel JB. Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone. J Pediatr. 2017;191(Dec):225–231.
   PubMedGoogle Scholar
• Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol. 1958;20:350–355.
   PubMedGoogle Scholar
• Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241–3248.
   PubMed Web of Science ®Google Scholar
• Kong Z, Qin P, Xiao S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097–1103.
   PubMed Web of Science ®Google Scholar
• Wang H, Huang M, Zhao Y, et al. Recombinant human thrombopoietin promotes platelet engraftment and improves prognosis of patients with myelodysplastic syndromes and aplastic anemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(10):1678–1684.
   PubMed Web of Science ®Google Scholar
• Grozovsky R, Jurak Begonja A, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat. 2015;21(1):47–54.
   Google Scholar
• Hoffmeister KM, Falet H. Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance. Thromb Res. 2016;141(Suppl 2):S68–S72.
   PubMed Web of Science ®Google Scholar
• Neunert C, Despotovic J, Haley K, et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016;63(8):1407–1413.
   PubMed Web of Science ®Google Scholar
• Ramaswamy K, Hsieh L, Leven E, et al. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr. 2014;165(3):600–605.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–1132.
   PubMed Web of Science ®Google Scholar
• Bussel JB, De Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315–325.
   PubMed Web of Science ®Google Scholar
• Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649–1658.
   PubMed Web of Science ®Google Scholar
• Ehrlich LA, Kwitkowski VE, Reaman G, et al. U.S. food and drug administration approval summary: eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia. Pediatr Blood Cancer. 2017 [Epub]. DOI:10.1002/pbc.26657
   Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536.
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394.
   PubMed Web of Science ®Google Scholar
• Bastian TW, Duck KA, Michalopoulos GC, et al. Eltrombopag, a thrombopoietin mimetic, crosses the blood–brain barrier and impairs iron-dependent hippocampal neuron dendrite development. J Thromb Haemost. 2017;15(3):565–574.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28–36.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45–54.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, McCrae KR. Treatment of chronic immune thrombocytopenia in children with romiplostim. Lancet. 2016;388(10039):4–6.
   PubMed Web of Science ®Google Scholar
• Steurer M, Quittet P, Papadaki HA, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol. 2017;98(2):112–120.
   PubMed Web of Science ®Google Scholar
• Lakhwani S, Perera M, Fernández-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372–377.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937–944.
   PubMed Web of Science ®Google Scholar
• Doobaree I, Nandigam R, Bennett D, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016;97(4):321–330.
   PubMed Web of Science ®Google Scholar
• Sayinalp N, Haznedaroğlu IC, Büyükaşik Y, et al. Protein C inhibitor and serum amyloid A in immune thrombocytopaenic purpura. J Int Med Res. 2004;32(1):62–65.
   PubMed Web of Science ®Google Scholar
• Ozcebe OI, Karakuş S, Haznedaroğlu IC. Plasma thrombospondin in immune thrombocytopenic purpura. J Int Med Res. 2002;30(1):52–55.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. ITP and thrombosis: an intriguing association. Blood Adv. 2017;1(24):2280.
   PubMed Web of Science ®Google Scholar
• Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172(2):262–273.
   PubMed Web of Science ®Google Scholar
• Marshall AL, Scarpone R, De Greef M, et al. Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica. 2016;101(12):e476–e478.
   PubMed Web of Science ®Google Scholar
• Kaznelson P. Verschwinden der hämorrhagische Diathese bei einem Falle von “essentieller thrombopenie” (Frank) nach Milzexstirpation. Splenogene thrombolytische Purpura. Wien Klin Wochenschr. 1916;29:1451–1454.
   Google Scholar
• Kumar S, Diehn FE, Gertz MA, et al. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol. 2002;81(6):312–319.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Devasia AJ, Viswabandya A, et al. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: splenectomy in ITP. Ann Hematol. 2016;95(9):1429–1434.
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–2634.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4):E267–E272.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835.
   PubMed Web of Science ®Google Scholar
• Thai LH, Mahévas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95(48):e5098.
   PubMed Web of Science ®Google Scholar
• Guan Y, Wang S, Xue F, et al. Long-term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol. 2017;98(3):235–241.
   PubMed Web of Science ®Google Scholar
• Vesely SK, Perdue JJ, Rizvi MA, et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Intern Med. 2004;140(2):112–120.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128(12):1625–1630.
   PubMed Web of Science ®Google Scholar
• Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative Latin American group on hemostasis and thrombosis. Blood. 1984;64(6):1179–1183.
   PubMed Web of Science ®Google Scholar
• Quiquandon I, Fenaux P, Caulier MT, et al. Re‐evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223–228.
   PubMed Web of Science ®Google Scholar
• Choudhary DR, Naithani R, Mahapatra M, et al. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008;93(10):e61–62.
   PubMedGoogle Scholar
• Perrotta S, Amendola G, Locatelli F, et al. Treatment with short‐term, high dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2003;121(1):143–147.
   PubMed Web of Science ®Google Scholar
• Liu APY, Cheuk DKL, Lee AHY, et al. Cyclosporin A for persistent or chronic immune thrombocytopenia in children. Ann Hematol. 2016;95(11):1881–1886.
   PubMed Web of Science ®Google Scholar
• Verlin M, Laros RK Jr, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol. 1976;1(1):97–104.
   PubMed Web of Science ®Google Scholar
• Joseph A, Evans DI. Immunosuppressive treatment of idiopathic thrombocytopenic purpura in children. Acta Paed Scand. 1982;71(3):467–469.
   PubMed Web of Science ®Google Scholar
• Miano M, Ramenghi U, Russo G, et al. Mycophenolate mofetil for the treatment of children withimmune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol. 2016;175(3):490–495.
   PubMed Web of Science ®Google Scholar
• Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171(4):625–630.
   PubMed Web of Science ®Google Scholar
• Zhang WG, Ji L, Cao XM, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sinica. 2005;26(5):598–602.
   PubMed Web of Science ®Google Scholar
• Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): a single institution’s experience. J Pediatr Hematol Oncol. 2017;39(6):420–424.
   PubMed Web of Science ®Google Scholar
• Sundar S, Moorleedursingh GS, Kumar K, et al. Danazol therapy in chronic idiopathic thrombocytopenic purpura. J Assoc Phys India. 1992;40(5):350–351.
   PubMedGoogle Scholar
• Fenaux P, Quiquandon I, Huart JJ, et al. The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases. Nouv Rev Française Hematol. 1986;32(2):143–146.
   Google Scholar
• Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22(8):727–733.
   PubMed Web of Science ®Google Scholar
• Vancine-Califani SMC, De Paula EV, Ozelo MC, et al. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets. 2008;19(7):489–495.
   PubMed Web of Science ®Google Scholar
• Patel AP, Patil AS. Dapsone for immune thrombocytopenic purpura in children and adults. Platelets. 2015;26(2):164–167.
   PubMed Web of Science ®Google Scholar
• Massimo L, Genova R, Marchi A, et al. More on vincristine in treatment of ITP in children. N Engl J Med. 1977;297(7):397–398.
   PubMed Web of Science ®Google Scholar
• Fresneau B, Petit A, Courcoux MF, et al. Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia. Am J Hematol. 2011;86(9):785–787.
   PubMed Web of Science ®Google Scholar
• Facon T, Caulier MT, Wattel E, et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994;86(3):678–680.
   PubMed Web of Science ®Google Scholar
• Newland A, Lee E-J, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25.
   PubMed Web of Science ®Google Scholar
• Mocsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387–402.
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of syk. Blood. 2009;113(14):3154–3160.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Arnold DM, Cooper N, et al. Long-term maintenance of platelet responses in adult patients with persistent/chronic immune thrombocytopenia treated with fostamatinib: 1-year efficacy and safety results. American Society of Hematology Annual Meeting (meeting abstract) Session: 311. Disorders of Platelet Number or Function: ITP: clinical aspects: abstract 2017; Nr. 16 Atlanta; 2017.
   Google Scholar
• Martins JP, Kennedy PJ, Santos HA, et al. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther. 2016;161(May):22–39.
   PubMedGoogle Scholar
• Brambell FW, Hemmings WA, Morris IG. A theoretical model of gammaglobulin catabolism. Nature. 1964;203(4952):1352–1355.
   PubMedGoogle Scholar
• Robak T, Jarque I, Musteata V, et al. Phase II, multiple-dose study of anti-FcRN antibody, rozanolixizumab (ucb7665), in patients with primary immune thrombocytopenia: interim analysis. American Society of Hematology Annual Meeting (meeting abstract) Session: 311. Disorders of Platelet Number or Function: ITP: clinical aspects: abstract 2017; Nr. 15; Atlanta; 2017.
   Google Scholar
• Zhou H, Hou Y, Liu X, et al. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost. 2015;113(5):1021–1034.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yunqi S, Zhou H, et al. Low-dose decitabine restores immune tolerance in ITP by modulating regulatory T cells. American Society of Hematology Annual Meeting (meeting abstract) Session: 311. Disorders of Platelet Number or Function: ITP: clinical aspects: abstract 2017; Nr. 229; Atlanta; 2017.
   Google Scholar